Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm

NCT05113355 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

23

Enrollment

OTHER

Sponsor class

Conditions

Neuroendocrine Tumors
Neuroendocrine Tumor Grade 3
Neuroendocrine Carcinoma
Neuroendocrine Neoplasm

Interventions

DRUG: Chidamide
DRUG: Sintilimab

Sponsor

Peking Union Medical College Hospital

Collaborators

[object Object]
[object Object]